{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T16:21:51Z","timestamp":1791044511894,"version":"4.1.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,10,17]],"date-time":"2023-10-17T00:00:00Z","timestamp":1697500800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,10,17]],"date-time":"2023-10-17T00:00:00Z","timestamp":1697500800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Neuroradiol"],"published-print":{"date-parts":[[2024,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Prasugrel is not approved for patients treated with flow diverters, which have a\u00a0high metal coverage ratio. However, robust antiplatelet therapy with prasugrel may prevent thromboembolic complications. We administered prasugrel and aspirin to all patients treated with flow diverters and reported the safety of the antiplatelet therapy regimen.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective, single-center study evaluated the angiographic and clinical data of consecutive patients treated with flow diverters for cerebral unruptured aneurysms between June 2020 and May 2022. All patients received dual antiplatelet therapy, including prasugrel and aspirin. The administration of prasugrel ended 3\u00a0or 6\u00a0months after the procedure, whereas aspirin use continued for at least 12\u00a0months. Periprocedural complications (&lt;\u202f30\u00a0days post-procedure) and delayed complications (&gt;\u202f30\u00a0days post-procedure) were recorded.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>During the study period, 120 unruptured aneurysms were treated with flow diverters in 110 patients. All patients, except one, survived longer than 12\u00a0months after the procedure. The rate of thromboembolic complications was 6.4%, and more than half of the patients had transient symptoms; one (0.9%) had a\u00a0major ischemic stroke. One patient (0.9%) each had an asymptomatic, small subarachnoid hemorrhage and significant hemorrhagic complications with melena. The rate of permanent neurological deficits was 1.8%, and the mortality rate was 0.9%.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Dual antiplatelet therapy comprising routine use of prasugrel and aspirin for flow diverter-implanted patients possibly contributed to a\u00a0low rate of thromboembolic complications and low risk of hemorrhagic complications.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00062-023-01355-2","type":"journal-article","created":{"date-parts":[[2023,10,17]],"date-time":"2023-10-17T04:02:08Z","timestamp":1697515328000},"page":"201-208","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Efficacy and Safety of Dual Antiplatelet Therapy with the Routine Use of Prasugrel for Flow Diversion of Cerebral Unruptured Aneurysms"],"prefix":"10.1007","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0147-5564","authenticated-orcid":false,"given":"Kenichiro","family":"Suyama","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ichiro","family":"Nakahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shoji","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Morioka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Tanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akiko","family":"Hasebe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sadayoshi","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,10,17]]},"reference":[{"key":"1355_CR1","doi-asserted-by":"publisher","unstructured":"Hankey GJ, Eikelboom JW. Aspirin resistance. Lancet. 2006;367:606\u201317. https:\/\/doi.org\/10.1016\/S0140-6736(06)68040-9.","DOI":"10.1016\/S0140-6736(06)68040-9"},{"key":"1355_CR2","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.ahj.2007.04.014","volume":"154","author":"JD Snoep","year":"2007","unstructured":"Snoep JD, Hovens MMC, Eikenboom JCJ, van der Bom JG, Jukema JW, Huisman MV. Clopidogrel nonresponsiveness in patients undergoing percutaneous coronary intervention with stenting: a systematic review and meta-analysis. Am Heart J. 2007;154:221\u201331. https:\/\/doi.org\/10.1016\/j.ahj.2007.04.014.","journal-title":"Am Heart J"},{"key":"1355_CR3","doi-asserted-by":"publisher","first-page":"891","DOI":"10.3171\/2014.6.JNS132448","volume":"121","author":"BJ Kim","year":"2014","unstructured":"Kim BJ, Kwon JY, Jung JM, et al. Association between silent embolic cerebral infarction and continuous increase of P2Y12 reaction units after neurovascular stenting. J Neurosurg. 2014;121:891\u20138. https:\/\/doi.org\/10.3171\/2014.6.JNS132448.","journal-title":"J Neurosurg"},{"key":"1355_CR4","doi-asserted-by":"publisher","first-page":"3795","DOI":"10.2174\/1381612811319210006","volume":"19","author":"US Tantry","year":"2013","unstructured":"Tantry US, Gurbel PA. Antiplatelet drug resistance and variability in response: the role of antiplatelet therapy monitoring. Curr Pharm Des. 2013;19:3795\u2013815. https:\/\/doi.org\/10.2174\/1381612811319210006.","journal-title":"Curr Pharm Des"},{"key":"1355_CR5","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.3174\/ajnr.A2051","volume":"31","author":"HS Kang","year":"2010","unstructured":"Kang HS, Kwon BJ, Kim JE, Han MH. Preinterventional clopidogrel response variability for coil embolization of intracranial aneurysms: clinical implications. AJNR Am J Neuroradiol. 2010;31:1206\u201310. https:\/\/doi.org\/10.3174\/ajnr.A2051.","journal-title":"AJNR Am J Neuroradiol"},{"key":"1355_CR6","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.3174\/ajnr.A4777","volume":"37","author":"MS Kim","year":"2016","unstructured":"Kim MS, Jo KI, Yeon JY, et al. Association between postprocedural infarction and antiplatelet drug resistance after coiling for unruptured intracranial aneurysms. AJNR Am J Neuroradiol. 2016;37:1099\u2013105. https:\/\/doi.org\/10.3174\/ajnr.A4777.","journal-title":"AJNR Am J Neuroradiol"},{"key":"1355_CR7","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1136\/intsurg-2015-011727","volume":"8","author":"T Asai","year":"2016","unstructured":"Asai T, Miyachi S, Izumi T, et al. Relationship between low response to clopidogrel and periprocedural ischemic events with coil embolization for intracranial aneurysms. J Neurointerv Surg. 2016;8:752\u20135. https:\/\/doi.org\/10.1136\/intsurg-2015-011727.","journal-title":"J Neurointerv Surg"},{"key":"1355_CR8","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1136\/ejhpharm-2017-001359","volume":"26","author":"IF Yaseen","year":"2019","unstructured":"Yaseen IF, Farhan HA, Abbas HM. Clopidogrel non-responsiveness in patients undergoing percutaneous coronary intervention using the VerifyNow test: frequency and predictors. Eur J Hosp Pharm Sci Pract. 2019;26:113\u20136. https:\/\/doi.org\/10.1136\/ejhpharm-2017-001359.","journal-title":"Eur J Hosp Pharm Sci Pract"},{"key":"1355_CR9","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","volume":"357","author":"SD Wiviott","year":"2007","unstructured":"Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357:2001\u201315. https:\/\/doi.org\/10.1056\/NEJMoa0706482.","journal-title":"N Engl J Med"},{"key":"1355_CR10","doi-asserted-by":"publisher","unstructured":"Wiviott SD, Braunwald E, McCabe CH, et al. Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a randomised trial. Lancet. 2008;371:1353\u201363. https:\/\/doi.org\/10.1016\/s0140-6736(08)60422-5.","DOI":"10.1016\/s0140-6736(08)60422-5"},{"key":"1355_CR11","doi-asserted-by":"publisher","unstructured":"Stone GW, Witzenbichler B, Weisz G, et al. Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study. Lancet. 2013;382:614\u201323. https:\/\/doi.org\/10.1016\/S0140-6736(13)61170-8.","DOI":"10.1016\/S0140-6736(13)61170-8"},{"key":"1355_CR12","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1136\/neurintsurg-2012-010334","volume":"5","author":"SH Akbari","year":"2013","unstructured":"Akbari SH, Reynolds MR, Kadkhodayan Y, Cross DT 3rd, Moran CJ. Hemorrhagic complications after prasugrel (Effient) therapy for vascular neurointerventional procedures. J Neurointerv Surg. 2013;5:337\u201343. https:\/\/doi.org\/10.1136\/neurintsurg-2012-010334.","journal-title":"J Neurointerv Surg"},{"key":"1355_CR13","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1177\/1591019916669090","volume":"23","author":"J Sedat","year":"2017","unstructured":"Sedat J, Chau Y, Gaudart J, Sachet M, Beuil S, Lonjon M. Prasugrel versus clopidogrel in stent-assisted coil embolization of unruptured intracranial aneurysms. Interv Neuroradiol. 2017;23:52\u20139. https:\/\/doi.org\/10.1177\/1591019916669090.","journal-title":"Interv Neuroradiol"},{"key":"1355_CR14","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1136\/neurintsurg-2012-010302","volume":"5","author":"WR Stetler","year":"2013","unstructured":"Stetler WR, Chaudhary N, Thompson BG, Gemmete JJ, Maher CO, Pandey AS. Prasugrel is effective and safe for neurointerventional procedures. J Neurointerv Surg. 2013;5:332\u20136. https:\/\/doi.org\/10.1136\/neurintsurg-2012-010302.","journal-title":"J Neurointerv Surg"},{"key":"1355_CR15","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1148\/radiol.2016160542","volume":"282","author":"CH Kim","year":"2017","unstructured":"Kim CH, Hwang G, Kwon OK, et al. P2Y12 reaction units threshold for implementing modified antiplatelet preparation in coil embolization of unruptured aneurysms: A prospective validation study. Radiology. 2017;282:542\u201351. https:\/\/doi.org\/10.1148\/radiol.2016160542.","journal-title":"Radiology"},{"key":"1355_CR16","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","volume":"3","author":"S Schulman","year":"2005","unstructured":"Schulman S, Kearon C, Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost. 2005;3:692\u20134. https:\/\/doi.org\/10.1111\/j.1538-7836.2005.01204.x.","journal-title":"J Thromb Haemost"},{"key":"1355_CR17","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1136\/neurintsurg-2020-016994","volume":"13","author":"S Higashiguchi","year":"2021","unstructured":"Higashiguchi S, Sadato A, Nakahara I, et al. Reduction of thromboembolic complications during the endovascular treatment of unruptured aneurysms by employing a tailored dual antiplatelet regimen using aspirin and prasugrel. J Neurointerv Surg. 2021;13:1044\u20138. https:\/\/doi.org\/10.1136\/neurintsurg-2020-016994.","journal-title":"J Neurointerv Surg"},{"key":"1355_CR18","doi-asserted-by":"publisher","first-page":"2060","DOI":"10.3174\/ajnr.A4864","volume":"37","author":"EJ Ha","year":"2016","unstructured":"Ha EJ, Cho WS, Kim JE, et al. Prophylactic antiplatelet medication in endovascular treatment of intracranial aneurysms: Low-dose prasugrel versus clopidogrel. AJNR Am J Neuroradiol. 2016;37:2060\u20135. https:\/\/doi.org\/10.3174\/ajnr.A4864.","journal-title":"AJNR Am J Neuroradiol"},{"key":"1355_CR19","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1093\/neuros\/nyx591","volume":"83","author":"HH Choi","year":"2018","unstructured":"Choi HH, Lee JJ, Cho YD, et al. Antiplatelet premedication for stent-assisted coil embolization of intracranial aneurysms: Low-dose prasugrel vs clopidogrel. Neurosurgery. 2018;83:981\u20138. https:\/\/doi.org\/10.1093\/neuros\/nyx591.","journal-title":"Neurosurgery"},{"key":"1355_CR20","doi-asserted-by":"publisher","first-page":"E52","DOI":"10.1093\/neuros\/nyy341","volume":"85","author":"WS Cho","year":"2019","unstructured":"Cho WS, Lee J, Ha EJ, et al. Low-dose prasugrel vs clopidogrel-based tailored premedication for endovascular treatment of cerebral aneurysms. Neurosurgery. 2019;85:E52\u20139. https:\/\/doi.org\/10.1093\/neuros\/nyy341.","journal-title":"Neurosurgery"},{"key":"1355_CR21","doi-asserted-by":"publisher","first-page":"681","DOI":"10.3174\/ajnr.A6004","volume":"40","author":"F Cagnazzo","year":"2019","unstructured":"Cagnazzo F, Perrini P, Lefevre PH, et al. Comparison of prasugrel and clopidogrel used as antiplatelet medication for endovascular treatment of unruptured intracranial aneurysms: A meta-analysis. Ajnr Am J Neuroradiol. 2019;40:681\u20136. https:\/\/doi.org\/10.3174\/ajnr.A6004.","journal-title":"Ajnr Am J Neuroradiol"},{"key":"1355_CR22","doi-asserted-by":"crossref","unstructured":"Saito S, Isshiki T, Kimura T, et al. Efficacy and safety of adjusted-dose prasugrel compared with clopidogrel in Japanese patients with acute coronary syndrome: The PRASFIT-ACS study. Circ J. 2014;78:1684\u201392. https:\/\/doi.org\/10.1253\/circj.cj-13-1482","DOI":"10.1253\/circj.CJ-13-1482"},{"key":"1355_CR23","doi-asserted-by":"publisher","first-page":"222","DOI":"10.5551\/jat.63473","volume":"30","author":"T Kitazono","year":"2023","unstructured":"Kitazono T, Kamouchi M, Matsumaru Y, et al. Efficacy and safety of prasugrel vs clopidogrel in thrombotic stroke patients with risk factors for ischemic stroke recurrence: A double-blind, phase III study (PRASTRO-III). J Atheroscler Thromb. 2023;30:222\u201336. https:\/\/doi.org\/10.5551\/jat.63473.","journal-title":"J Atheroscler Thromb"},{"key":"1355_CR24","doi-asserted-by":"publisher","first-page":"108","DOI":"10.3174\/ajnr.A4111","volume":"36","author":"DF Kallmes","year":"2015","unstructured":"Kallmes DF, Hanel R, Lopes D, et al. International retrospective study of the pipeline embolization device: a multicenter aneurysm treatment study. AJNR Am J Neuroradiol. 2015;36:108\u201315. https:\/\/doi.org\/10.3174\/ajnr.A4111.","journal-title":"AJNR Am J Neuroradiol"},{"key":"1355_CR25","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1136\/neurintsurg-2019-015091","volume":"15","author":"R Hanel","year":"2023","unstructured":"Hanel R, Cortez GM, Lopes DK, et al. Prospective study on embolization of intracranial aneurysms with the pipeline device (PREMIER study): 3-year results with the application of a flow diverter specific occlusion classification. J Neurointerv Surg. 2023;15:248\u201354. https:\/\/doi.org\/10.1136\/neurintsurg-2019-015091.","journal-title":"J Neurointerv Surg"},{"key":"1355_CR26","doi-asserted-by":"publisher","first-page":"128","DOI":"10.3174\/ajnr.A3621","volume":"35","author":"JE Delgado Almandoz","year":"2014","unstructured":"Delgado Almandoz JE, Crandall BM, Scholz JM, et al. Last-recorded P2Y12 reaction units value is strongly associated with thromboembolic and hemorrhagic complications occurring up to 6 months after treatment in patients with cerebral aneurysms treated with the pipeline embolization device. AJNR Am J Neuroradiol. 2014;35:128\u201335. https:\/\/doi.org\/10.3174\/ajnr.A3621.","journal-title":"AJNR Am J Neuroradiol"},{"key":"1355_CR27","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1136\/neurintsurg-2014-011111","volume":"7","author":"LA Tan","year":"2015","unstructured":"Tan LA, Keigher KM, Munich SA, Moftakhar R, Lopes DK. Thromboembolic complications with Pipeline Embolization Device placement: impact of procedure time, number of stents and pre-procedure P2Y12 reaction unit (PRU) value. J Neurointerv Surg. 2015;7:217\u201321. https:\/\/doi.org\/10.1136\/neurintsurg-2014-011111.","journal-title":"J Neurointerv Surg"},{"key":"1355_CR28","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.jjcc.2010.10.007","volume":"57","author":"K Yamamoto","year":"2011","unstructured":"Yamamoto K, Hokimoto S, Chitose T, et al. Impact of CYP2C19 polymorphism on residual platelet reactivity in patients with coronary heart disease during antiplatelet therapy. J Cardiol. 2011;57:194\u2013201. https:\/\/doi.org\/10.1016\/j.jjcc.2010.10.007.","journal-title":"J Cardiol"},{"key":"1355_CR29","doi-asserted-by":"crossref","unstructured":"Mega JL, Simon T, Collet JP, et al. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis: A meta-analysis. JAMA. 2010;304:1821\u201330. https:\/\/doi.org\/10.1001\/jama.2010.1543","DOI":"10.1001\/jama.2010.1543"},{"key":"1355_CR30","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1007\/s11239-018-1714-2","volume":"46","author":"T Kitazono","year":"2018","unstructured":"Kitazono T, Ikeda Y, Nishikawa M, Yoshiba S, Abe K, Ogawa A. Influence of cytochrome P450 polymorphisms on the antiplatelet effects of prasugrel in patients with non-cardioembolic stroke previously treated with clopidogrel. J Thromb Thrombolysis. 2018;46:488\u201395. https:\/\/doi.org\/10.1007\/s11239-018-1714-2.","journal-title":"J Thromb Thrombolysis"},{"key":"1355_CR31","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1097\/FJC.0b013e3181dd0ec2","volume":"56","author":"JA Jakubowski","year":"2010","unstructured":"Jakubowski JA, Li YG, Small DS, et al. A comparison of the VerifyNow P2Y12 point-of-care device and light transmission aggregometry to monitor platelet function with prasugrel and clopidogrel: an integrated analysis. J Cardiovasc Pharmacol. 2010;56:29\u201337. https:\/\/doi.org\/10.1097\/FJC.0b013e3181dd0ec2.","journal-title":"J Cardiovasc Pharmacol"},{"key":"1355_CR32","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1093\/neuros\/nyx079","volume":"81","author":"JM Moore","year":"2017","unstructured":"Moore JM, Adeeb N, Shallwani H, et al. A multicenter cohort comparison study of the safety, efficacy, and cost of ticagrelor compared to clopidogrel in aneurysm flow diverter procedures. Neurosurgery. 2017;81:665\u201371. https:\/\/doi.org\/10.1093\/neuros\/nyx079.","journal-title":"Neurosurgery"},{"key":"1355_CR33","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.3174\/ajnr.A7216","volume":"42","author":"KY Park","year":"2021","unstructured":"Park KY, Ozaki T, Kostynskyy A, et al. Ticagrelor versus clopidogrel in the dual antiplatelet regimen for intracranial stenting or flow-diverter treatment for unruptured cerebral aneurysms: a single-center cohort study. Ajnr Am J Neuroradiol. 2021;42:1638\u201344. https:\/\/doi.org\/10.3174\/ajnr.A7216.","journal-title":"Ajnr Am J Neuroradiol"},{"key":"1355_CR34","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1136\/neurintsurg-2013-010699","volume":"6","author":"RA Hanel","year":"2014","unstructured":"Hanel RA, Taussky P, Dixon T, et al. Safety and efficacy of ticagrelor for neuroendovascular procedures. A single center initial experience. J NeuroIntervent Surg. 2014;6:320\u20132. https:\/\/doi.org\/10.1136\/neurintsurg-2013-010699.","journal-title":"J NeuroIntervent Surg"},{"key":"1355_CR35","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1136\/neurintsurg-2018-014363","volume":"11","author":"NW Manning","year":"2019","unstructured":"Manning NW, Cheung A, Phillips TJ, Wenderoth JD. Pipeline shield with single antiplatelet therapy in aneurysmal subarachnoid haemorrhage: multicentre experience. J Neurointerv Surg. 2019;11:694\u20138. https:\/\/doi.org\/10.1136\/neurintsurg-2018-014363.","journal-title":"J Neurointerv Surg"},{"key":"1355_CR36","doi-asserted-by":"publisher","first-page":"300060519879580","DOI":"10.1177\/0300060519879580","volume":"48","author":"P Bhogal","year":"2020","unstructured":"Bhogal P, Bleise C, Chudyk J, et al. The p48_HPC antithrombogenic flow diverter: initial human experience using single antiplatelet therapy. J Int Med Res. 2020;48:300060519879580. https:\/\/doi.org\/10.1177\/0300060519879580.","journal-title":"J Int Med Res"},{"key":"1355_CR37","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1136\/neurintsurg-2020-017262","volume":"13","author":"LH de Castro-Afonso","year":"2021","unstructured":"de Castro-Afonso LH, Nakiri GS, Abud TG, et al. Treatment of distal unruptured intracranial aneurysms using a surface-modified flow diverter under prasugrel monotherapy: a pilot safety trial. J Neurointerv Surg. 2021;13:647\u201351. https:\/\/doi.org\/10.1136\/neurintsurg-2020-017262.","journal-title":"J Neurointerv Surg"},{"key":"1355_CR38","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1177\/15910199211029503","volume":"28","author":"P Bhogal","year":"2022","unstructured":"Bhogal P, Petrov A, Rentsenkhu G, et al. Early clinical experience with the p48MW HPC and p64MW HPC flow diverters in the anterior circulation aneurysm using single anti-platelet treatment. Interv Neuroradiol. 2022;28:266\u201376. https:\/\/doi.org\/10.1177\/15910199211029503.","journal-title":"Interv Neuroradiol"},{"key":"1355_CR39","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1007\/s00270-022-03153-8","volume":"45","author":"V Hellstern","year":"2022","unstructured":"Hellstern V, Aguilar PM, Henkes E, et al. Use of a p64 MW flow diverter with hydrophilic polymer coating (HPC) and prasugrel single antiplatelet therapy for the treatment of unruptured anterior circulation aneurysms: Safety data and short-term occlusion rates. Cardiovasc Radiol. 2022;45:1364\u201374. https:\/\/doi.org\/10.1007\/s00270-022-03153-8.","journal-title":"Cardiovasc Radiol"},{"key":"1355_CR40","doi-asserted-by":"publisher","first-page":"159101992311777","DOI":"10.1177\/15910199231177745","volume":"23","author":"Y Ma","year":"2023","unstructured":"Ma Y, Madjidyar J, Schubert T, et al. Single antiplatelet regimen in flow diverter treatment of cerebral aneurysms: The drug matters. A systematic review and meta-analysis. Interv Neuroradiol. 2023;23:15910199231177745. https:\/\/doi.org\/10.1177\/15910199231177745.","journal-title":"Interv Neuroradiol"}],"container-title":["Clinical Neuroradiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00062-023-01355-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00062-023-01355-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00062-023-01355-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,21]],"date-time":"2024-02-21T09:04:58Z","timestamp":1708506298000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00062-023-01355-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,17]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["1355"],"URL":"https:\/\/doi.org\/10.1007\/s00062-023-01355-2","relation":{},"ISSN":["1869-1439","1869-1447"],"issn-type":[{"value":"1869-1439","type":"print"},{"value":"1869-1447","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,17]]},"assertion":[{"value":"28 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"K.\u00a0Suyama, I.\u00a0Nakahara, S.\u00a0Matsumoto, J.\u00a0Morioka, J.\u00a0Tanabe, A.\u00a0Hasebe and S.\u00a0Watanabe declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was approved by the Institutional Ethics Committee (approval number: HM 22-125). <i>Informed consent:<\/i> The need for written informed consent was waived because the option to opt out of the study was posted on the institutional website and as the study had a\u00a0retrospective design and involved the analysis of routine follow-up data.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical standards"}}]}}